Immuneering Corporation, a biopharmaceutical company based in Cambridge, United States, operates within the health care sector and is listed on the Nasdaq stock exchange. As of May 13, 2026, the company’s close price stood at $5.14, with a market capitalization of approximately $348 million. Over the past year, Immuneering Corp’s stock has experienced significant volatility, reaching a 52-week high of $10.08 on September 21, 2025, and a low of $1.40 on May 21, 2025. The company’s price-to-earnings ratio is currently -4.19, reflecting its financial performance and market valuation.
Immuneering Corporation specializes in the development of diagnostic platforms that integrate human data, novel biology, and chemistry, alongside translational planning. This innovative approach aims to create new therapies for patients suffering from debilitating oncologic and neurologic diseases. By focusing on these critical areas, Immuneering Corp serves a vital role in advancing disease detection and treatment methodologies.
The company’s strategic emphasis on harnessing cutting-edge science and technology positions it as a key player in the biopharmaceutical industry. Immuneering Corp’s efforts are directed towards addressing unmet medical needs, particularly in the realms of oncology and neurology, where the demand for effective diagnostic and therapeutic solutions is high.
Operating primarily in the United States, Immuneering Corporation leverages its unique expertise to serve a diverse customer base. The company’s commitment to innovation and patient care is evident in its ongoing research and development initiatives, which are designed to translate scientific discoveries into practical applications that can improve patient outcomes.
For those interested in learning more about Immuneering Corporation’s work and offerings, additional information is available on their official website, www.immuneering.com . Investors and stakeholders can also track the company’s performance and trading activities on the Nasdaq stock exchange, where Immuneering Corp is publicly traded.
